Reports Q2 revenue $793.29M, consensus $765.2M. “We are pleased to report solid results in the second quarter driven by continued strength in our core Sleep and Respiratory product lines.” said Richard Barasch, Chairman and Interim CEO of AdaptHealth. “We have spent considerable effort creating and beginning to implement a comprehensive plan to resume market growth in our Diabetes line of business and saw meaningful sequential improvement. We were especially pleased with our cash generation for the first half of the year and with the execution to date of our cost-management program.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AHCO: